Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	11/30/2004 2:12:59 PM
	Read Replies (2) of 590

...CP-675,206 is a potential cancer medicine developed in collaboration with Abgenix. Unlike traditional chemotherapy agents that kill all susceptible cells, CP-675,206 fights cancer by helping the body's immune system recognize and selectively destroy cancer cells. In one early trial, the compound was given to patients with a metastatic melanoma that is usually fatal. Six patients achieved complete remission, and experienced side effects that were mild and manageable. This compound has just entered Phase II clinical testing.... Message 20813098

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next